IntegraDose Compounding Services LLC recalled 853 bags of Oxytocin 30 Units/500 mL on September 16, 2025. Testing revealed these IV bags contain no oxytocin, posing serious health risks. The recall affects products distributed nationwide in the USA.
Subpotent Drug: Testing revealed there was no oxytocin in the IV bag.
Consumers and healthcare providers should stop using this product immediately. Contact IntegraDose Compounding Services LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Oxytocin 30 Units/500 mL in 0.9% Sodium Chloride for intravenous use. Lot number is 20250620OXY-1 with an expiration date of October 18, 2025. The product was distributed nationwide.
Testing revealed that the recalled IV bags contain no oxytocin, rendering them ineffective for use in medical settings. This poses a high health risk, especially in situations where oxytocin is critical for labor induction or management.
No specific injuries or incidents have been reported related to this recall. However, the lack of the active ingredient could lead to severe complications in patients requiring oxytocin.
Healthcare providers and consumers should stop using this product immediately. Contact IntegraDose Compounding Services LLC or your healthcare provider for guidance and further instructions.
For more details, contact IntegraDose Compounding Services LLC at the address 719 Kasota Ave SE, Minneapolis, MN 55414-2842. Visit the FDA recall page for updates: https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0015-2026.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.